Health Care Technology
Company Overview of Proteus Digital Health, Inc.
Proteus Digital Health, Inc. operates as a digital medicines company. The company focuses on developing products, services, and data systems based on integrating medicines with ingestible, wearable, mobile, and cloud computing. Its digital health feedback technology provides a view into an individual’s personal health choices and physiologic response, allowing patients to manage their health, and collaborate with caregivers and clinicians. Proteus Digital Health, Inc. was formerly known as Proteus Biomedical, Inc. and changed its name to Proteus Digital Health, Inc. in July 2012. Proteus Digital Health, Inc. was founded in 2001 and is headquartered in Redwood City, California. As of February...
2600 Bridge Parkway
Redwood City, CA 94065
Founded in 2001
Key Executives for Proteus Digital Health, Inc.
Co-Founder, Chief Executive Officer and President
Co-Founder and Chief Technologist
Co-Founder and Chief Medical Officer
Compensation as of Fiscal Year 2016.
Proteus Digital Health, Inc. Key Developments
Proteus Digital Health Announces Management Changes
Nov 17 15
Proteus Digital Health announced three executive appointments in order to propel the company’s commercialization and infrastructure for growth. Healthcare industry veteran Molly O’Neill joins the executive team as Chief Commercial Officer, Jonathan Symonds CBE, Chairman of HSBC Bank PLC, is appointed to Chairman of the Board and Shumeet Banerji, Ph.D., is appointed to the company’s Board of Directors. In her role as Chief Commercial Officer, O’Neill will lead partnerships with major health systems, payers and key provider customers in the United States. O’Neill brings over 30 years of experience in developing growth strategies to increase market share and revenues of academic, not for profit and investor owned health care institutions. O’Neill comes to Proteus from Tenet Health, where she served on the management team as senior vice president of business development. Jonathan Symonds is Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-executive Director of Genomics England. Formerly, Symonds was Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc. Symonds has served on the Proteus Board of Directors since June of 2014 and will continue advising the company on strategy, financial management and corporate governance in his new role as Chairman. Shumeet Banerji, Ph.D., is founder and partner of Condorcet, LP an investment and advisory firm. Banerji retired from Booz & Company Inc. in 2013 having served as its founding Chief Executive Officer. He formerly held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally, where he advised public and private sector entities at the Board level. He serves on the Board of HP, Inc. and Innocoll, AG. Banerji will provide oversight on Proteus’ corporate strategy and operational performance among other topics of critical importance to the company.
Proteus Digital Health, Inc. Presents at FT Digital Health Summit USA, Oct-28-2015 09:10 AM
Oct 25 15
Proteus Digital Health, Inc. Presents at FT Digital Health Summit USA, Oct-28-2015 09:10 AM. Venue: The Westin New York, Times Square, New York NY 10036, United States. Speakers: Andrew M. Thompson, Co-Founder, Chief Executive Officer and President.
U.S. FDA Accepts First Digital Medicine New Drug Application for Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health
Sep 10 15
Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health announced that the United States Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) for the combination product of ABILIFY (aripiprazole) embedded with a Proteus ingestible sensor in a single tablet is sufficiently complete to allow for a substantive review and is considered filed as of September 8, 2015. This is the first time an FDA-approved medication (ABILIFY) has been combined and submitted for approval with a sensor within the medication tablet (the Proteus ingestible sensor) to measure actual medication-taking patterns and physiologic response. This objective information is communicated to the patient - and with the consent of the patient - to the patient’s physician and/or caregiver. Digital Medicines may enable improved patient medication adherence and better informed physician decision-making to tailor treatment to the patient’s needs. An estimated average of 50% of patients with chronic diseases in developed countries do not take medicines as prescribed, possibly limiting the effectiveness of those medicines. In the U.S., this may result in an estimated $100-$300 billion in avoidable healthcare costs due to direct costs such as unnecessary escalation of treatment as well as indirect costs. For example, patients suffering from chronic mental disorders such as schizophrenia are often required to take medication for long periods, and it is not unusual for these patients to discontinue taking their medication, or not take their medication as prescribed, which can lead to disease relapse and recurrence. The ABILIFY tablet contains an ingestible sensor that communicates with a wearable sensor patch and a medical software application for measuring adherence in the treatment of adults with schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and as adjunctive therapy for the treatment of major depressive disorder in adults. If approved by the FDA, healthcare professionals will have the ability to prescribe ABILIFY tablets with the Proteus ingestible sensor embedded in the tablet. This drug-device product can provide the patient with a treatment option to help manage symptoms while allowing the caregiver and healthcare professional to measure medication adherence and other patient metrics. This unique system is filed as an NDA, where the FDA Center for Devices and Radiological Health (CDRH)-cleared ingestible sensor from Proteus will be embedded at the point of manufacture with the FDA Center for Drug Evaluation and Research (CDER)-approved ABILIFY as a combination drug-device, communicating with the Proteus patch and associated medical software. When ABILIFY with the embedded ingestible sensor is taken, the ingestible sensor sends a signal to the wearable Proteus patch after it reaches the stomach. The patch records and time-stamps the information from the ingestible sensor in addition to collecting other patient metrics, including rest, body angle and activity patterns. This information is recorded and relayed to patients on a mobile phone or other Bluetooth-enabled device, and only with their consent, to their physician and/or their caregivers. Patients view the information using a secure and local software application on their mobile phone or device. Physicians and caregivers view the data using secure web portals. ABILIFY is indicated for: Use as an adjunctive therapy to antidepressants in adults with Major Depressive Disorder who have had an inadequate response to antidepressant therapy; acute treatment of manic or mixed episodes associated with Bipolar I Disorder as monotherapy and as an adjunct to lithium or valproate in adult and treatment of Schizophrenia in adults. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). Although the causes of death were varied, most of the deaths appeared to be cardiovascular (e.g., heart failure, sudden death) or infectious in nature. ABILIFY is not approved for the treatment of patients with dementia-related psychosis. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of adjunctive ABILIFY or another antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increased risk of suicidality in adults beyond age 24. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. ABILIFY is not approved for use in pediatric patients with depression. Orthostatic Hypotension 'ABILIFY may be associated with orthostatic hypotension and should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension. Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia, and agranulocytosis have been reported with antipsychotics, including ABILIFY. Patients with history of a clinically significant low white blood cell (WBC) count or drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of ABILIFY should be considered at the first sign of a clinically significant decline in WBC count in the absence of other causative factors. Seizures/Convulsions: As with other antipsychotic drugs, ABILIFY should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold. Potential for Cognitive and Motor Impairment: Like other antipsychotics, ABILIFY may have the potential to impair judgment, thinking, or motor skills. Patients should not drive or operate hazardous machinery until they are certain ABILIFY does not affect them adversely. Body Temperature Regulation: Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotics. Appropriate care is advised for patients who may exercise strenuously, be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or be subject to dehydration.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 15, 2016